Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Dna X (SONM) EBITDA (2018 - 2025)

Dna X filings provide 8 years of EBITDA readings, the most recent being $4.7 million for Q4 2025.

  • On a quarterly basis, EBITDA fell 44.74% to $4.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$5.4 million, a 74.39% decrease, with the full-year FY2025 number at -$5.4 million, down 74.39% from a year prior.
  • EBITDA hit $4.7 million in Q4 2025 for Dna X, up from -$4.0 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $8.4 million in Q4 2024 to a low of -$11.7 million in Q4 2021.
  • Median EBITDA over the past 5 years was -$2.5 million (2024), compared with a mean of -$3.0 million.
  • The widest YoY moves for EBITDA: up 772.11% in 2024, down 966.13% in 2024.
  • Dna X's EBITDA stood at -$11.7 million in 2021, then soared by 90.98% to -$1.1 million in 2022, then fell by 18.51% to -$1.3 million in 2023, then skyrocketed by 772.11% to $8.4 million in 2024, then crashed by 44.74% to $4.7 million in 2025.
  • The last three reported values for EBITDA were $4.7 million (Q4 2025), -$4.0 million (Q3 2025), and -$6.7 million (Q2 2025) per Business Quant data.